Lexeo Therapeutics News and Activities

Presence

Lexeo Therapeutics develops genetic medicines for heart and brain diseases. Its main services include gene therapy research and clinical development for hospitals, physicians, and patients with severe inherited or chronic conditions.

Lexeo Therapeutics products and services overview:

Gene therapies
Cardiovascular treatments
Neurology treatments
Clinical development
Genetic medicine

Revenue: ~$0 million

Employees: 90

Headquarters: New York, United States (USA)

Lexeo Therapeutics is one of the...

Lexeo Therapeutics is a company listed under the stock ticker LXEO (US).

Executives

View the org chart displaying its 26 main executives

Most searched biographies at Lexeo Therapeutics

Popular executive movements at Lexeo Therapeutics

Laura Sepp-Lorenzino has joined the company as Director (posted on April 30 2026).
Sandi See Tai, Chief Development Officer, has left the company (posted on January 27 2026).
Jenny Robertson, Chief Legal and Administrative Officer, has left the company (posted on January 27 2026).

Click here to view some more movements at Lexeo Therapeutics

Create your alert
to follow the executive moves at Lexeo Therapeutics.